Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy

Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy

Anti-programmed cell death-1 (PD-1) antibodies are regarded as a risk factor for insulin-dependent diabetes mellitus as a side-effect. While a small number of cases have been reported, evidence remains limited. This is the first report of an Asian patient developing insulin-dependent diabetes during anti-PD-1 therapy. A 55-year-old euglycemic woman receiving nivolumab for malignant melanoma sho...

Metabolomics and Cell Therapy in Diabetes Mellitus

Diabetes with a broad spectrum of complications has become a global epidemic metabolic disorder. Till now, several pharmaceutical and non-pharmaceutical therapeutic approaches were applied for its treatment. Cell-based therapies have become promising methods for diabetes treatment. Better understanding of diabetes pathogenesis and identification of its specific biomarkers along with evaluation ...

Fulminant Type 1 Diabetes Mellitus in IRS-2 Deficient Mice

Type 1 diabetes mellitus (T1DM), one of two major forms of diabetes, results from nearly complete destruction of pancreatic beta (┚) cells. According to the classification of diabetes made by the American Diabetes Association, T1DM is divided into two subtypes: immunemediated (type 1A) and idiopathic (type 1B) (American Diabetes Association, 2008). Fulminant type 1 diabetes mellitus (FT1DM), wh...

Stem Cell Therapy for Type-1 Diabetes Mellitus

Stem Cell Therapy for Type-1 Diabetes Mellitus